Globally, more than 850 million people have chronic kidney disease (CKD). In the United States, it affects more than 37 million (15% of the adult population). 15 million of these patients have both CKD and diabetes type 2. There is a rapid need for early disease assessment, diagnosis and treatment. If not addressed at an early stage, significant kidney function loss can develop.
Traditional kidney testing is often unreliable. “Standard risk stratification tools for progression of kidney disease have limitations, and lack precision at an individual level.” Every patient and every kidney disease are different. Until now, it has been difficult to assess whether a patient will progress at a low-risk or a high-risk rate.
KidneyIntelX (created by Renalytix) can reliably help patients understand their exact risk. It “yields a simple-to-understand, custom risk score, identifying adult patients with type 2 diabetes and chronic kidney disease stages 1-3b, who are at low, intermediate or high risk for rapid progressive decline in kidney function.”
KidneyIntelX uses quantitative immunoassay (used to measure the amount of therapeutic products in a biologic matrix, such as plasma or serum) and clinical data combined with a machine learning algorithm to find a specific score for a patient’s 5 year risk for disease progression or decline. *KidneyIntelX has received breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Test reports and risk assessment:
Testing with KidneIntelX is done during CKD stages 1-3b. This allows doctors and patients the appropriate amount of time to alter treatment plans if needed. “KidneyIntelX has a growing body of evidence via validation, utility and economic studies, including a demonstrated 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function vs current standard of care.”
See commonly asked questions HERE.
Payment and insurance options HERE.
Resources and support HERE.
about the author
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.